Tapewire

Nasdaq · USD

DXCM

DEXCOM INC

Export transactions ↓
Tapewire entity
3114
SEC CIK
0001093557
Parsed reports
937

Last 12 months

Inside the activity.

2 purchase rows · 30 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202523
Dec 202500
Jan 202600
Feb 202601
Mar 202601
Apr 202601
May 202603
Jun 202605
Jul 202604
Aug 202607
Sep 202605
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
May 03, 2021 Filed May 5, 2021 21:35 UTC
SAYER KEVIN RDirector · Chairman, CEO & President
SaleCommon Stock 300 $384.91 $115,473.00
Disclosure

SEC source: 0001093557-21-000128 · edgardoc.xml · nonDerivative · entry 6

SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,053

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2020, and amended effective December 16, 2020. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer.

F3 · balance_after: Included in this number are 42,356 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 11,943 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

Read SEC document
May 03, 2021 Filed May 5, 2021 21:35 UTC
SAYER KEVIN RDirector · Chairman, CEO & President
SaleCommon Stock 500 $382.48 $191,240.00
Disclosure

SEC source: 0001093557-21-000128 · edgardoc.xml · nonDerivative · entry 5

SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,353

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2020, and amended effective December 16, 2020. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer.

F3 · balance_after: Included in this number are 42,356 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 11,943 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

Read SEC document
May 03, 2021 Filed May 5, 2021 21:35 UTC
SAYER KEVIN RDirector · Chairman, CEO & President
SaleCommon Stock 126 $378.99 $47,752.74
Disclosure

SEC source: 0001093557-21-000128 · edgardoc.xml · nonDerivative · entry 4

SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,853

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2020, and amended effective December 16, 2020. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer.

F3 · balance_after: Included in this number are 42,356 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 11,943 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

Read SEC document
May 03, 2021 Filed May 5, 2021 21:35 UTC
SAYER KEVIN RDirector · Chairman, CEO & President
SaleCommon Stock 248 $377.97 $93,736.81
Disclosure

SEC source: 0001093557-21-000128 · edgardoc.xml · nonDerivative · entry 3

SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,979

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2020, and amended effective December 16, 2020. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer.

F5 · price: This transaction was executed in multiple trades at prices ranging from $377.85 to $378.00. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · balance_after: Included in this number are 42,356 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 11,943 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

Read SEC document
May 03, 2021 Filed May 5, 2021 21:35 UTC
SAYER KEVIN RDirector · Chairman, CEO & President
SaleCommon Stock 487 $376.98 $183,590.14
Disclosure

SEC source: 0001093557-21-000128 · edgardoc.xml · nonDerivative · entry 2

SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,227

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2020, and amended effective December 16, 2020. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer.

F4 · price: This transaction was executed in multiple trades at prices ranging from $376.850 to $377.374. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · balance_after: Included in this number are 42,356 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 11,943 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

Read SEC document
May 03, 2021 Filed May 5, 2021 21:35 UTC
SAYER KEVIN RDirector · Chairman, CEO & President
SaleCommon Stock 2,543 $376.33 $957,014.31
Disclosure

SEC source: 0001093557-21-000128 · edgardoc.xml · nonDerivative · entry 1

SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,714

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2020, and amended effective December 16, 2020. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer.

F2 · price: This transaction was executed in multiple trades at prices ranging from $375.80 to $376.74. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · balance_after: Included in this number are 42,356 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 11,943 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

Read SEC document
April 26, 2021 Filed Apr 27, 2021 22:27 UTC
Murphy Patrick MichaelEVP, Chief Legal Officer
SaleCommon Stock 500 $415.83 $207,915.00
Disclosure

SEC source: 0001093557-21-000121 · edgardoc.xml · nonDerivative · entry 1

Murphy Patrick Michael · CIK 0001692785 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,241

F1 · shares: On August 28, 2020, Mr. Murphy adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Murphy. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · balance_after: Included in this number are 15,413 unvested restricted stock units, 5,634 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,905 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

Read SEC document
April 23, 2021 Filed Apr 27, 2021 00:09 UTC
Pacelli Steven RobertManaging Dir., Dexcom Ventures
SaleCommon Stock 347 $411.32 $142,727.10
Disclosure

SEC source: 0001093557-21-000117 · edgardoc.xml · nonDerivative · entry 3

Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,400

F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F5 · price: This transaction was executed in multiple trades at prices ranging from $411.21 to $411.48. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

Read SEC document
April 23, 2021 Filed Apr 27, 2021 00:09 UTC
Pacelli Steven RobertManaging Dir., Dexcom Ventures
SaleCommon Stock 436 $410.69 $179,058.97
Disclosure

SEC source: 0001093557-21-000117 · edgardoc.xml · nonDerivative · entry 2

Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,747

F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F4 · price: This transaction was executed in multiple trades at prices ranging from $409.965 to $410.820. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

Read SEC document
April 23, 2021 Filed Apr 27, 2021 00:09 UTC
Pacelli Steven RobertManaging Dir., Dexcom Ventures
SaleCommon Stock 296 $408.58 $120,941.07
Disclosure

SEC source: 0001093557-21-000117 · edgardoc.xml · nonDerivative · entry 1

Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,183

F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $408.55 to $408.64. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

Read SEC document
April 15, 2021 Filed Apr 16, 2021 20:44 UTC
Flynn Paul REVP, Global Revenue
SaleCommon Stock 758 $400.00 $303,200.00
Disclosure

SEC source: 0001093557-21-000115 · edgardoc.xml · nonDerivative · entry 1

Flynn Paul R · CIK 0001850141 · EVP, Global Revenue

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,306

F1 · shares: On December 11, 2020, Mr. Flynn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Flynn. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · balance_after: Included in this number are 12,306 unvested restricted stock units, 5,634 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,916 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 2,756 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

Read SEC document
April 05, 2021 Filed Apr 7, 2021 21:05 UTC
SAYER KEVIN RDirector · Chairman, CEO & President
SaleCommon Stock 1,179 $367.41 $433,176.98
Disclosure

SEC source: 0001093557-21-000107 · edgardoc.xml · nonDerivative · entry 3

SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,257

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2020, and amended effective December 16, 2020. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer.

F5 · price: This transaction was executed in multiple trades at prices ranging from $367.17 to $367.50. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · balance_after: Included in this number are 42,356 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 11,943 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

Read SEC document
April 05, 2021 Filed Apr 7, 2021 21:05 UTC
SAYER KEVIN RDirector · Chairman, CEO & President
SaleCommon Stock 3,567 $366.84 $1,308,535.76
Disclosure

SEC source: 0001093557-21-000107 · edgardoc.xml · nonDerivative · entry 2

SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,436

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2020, and amended effective December 16, 2020. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer.

F4 · price: This transaction was executed in multiple trades at prices ranging from $366.176 to $367.165. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · balance_after: Included in this number are 42,356 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 11,943 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

Read SEC document
April 05, 2021 Filed Apr 7, 2021 21:05 UTC
SAYER KEVIN RDirector · Chairman, CEO & President
SaleCommon Stock 1,475 $365.67 $539,369.15
Disclosure

SEC source: 0001093557-21-000107 · edgardoc.xml · nonDerivative · entry 1

SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,003

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2020, and amended effective December 16, 2020. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer.

F2 · price: This transaction was executed in multiple trades at prices ranging from $365.120 to $366.108. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · balance_after: Included in this number are 42,356 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 11,943 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

Read SEC document
March 26, 2021 Filed Mar 30, 2021 21:45 UTC
Murphy Patrick MichaelEVP, Chief Legal Officer
SaleCommon Stock 500 $350.00 $175,000.00
Disclosure

SEC source: 0001093557-21-000099 · edgardoc.xml · nonDerivative · entry 1

Murphy Patrick Michael · CIK 0001692785 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,741

F1 · shares: On August 28, 2020, Mr. Murphy adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Murphy. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · balance_after: Included in this number are 15,413 unvested restricted stock units, 5,634 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,905 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

Read SEC document
March 23, 2021 Filed Mar 25, 2021 00:18 UTC
Pacelli Steven RobertManaging Dir., Dexcom Ventures
SaleCommon Stock 166 $362.30 $60,141.42
Disclosure

SEC source: 0001093557-21-000093 · edgardoc.xml · nonDerivative · entry 5

Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,479

F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F5 · price: This transaction was executed in multiple trades at prices ranging from $362.13 to $362.45. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected.

F2 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

Read SEC document
March 23, 2021 Filed Mar 25, 2021 00:18 UTC
Pacelli Steven RobertManaging Dir., Dexcom Ventures
SaleCommon Stock 229 $360.90 $82,645.66
Disclosure

SEC source: 0001093557-21-000093 · edgardoc.xml · nonDerivative · entry 4

Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,645

F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F4 · price: This transaction was executed in multiple trades at prices ranging from $360.805 to $361.590. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

Read SEC document
March 23, 2021 Filed Mar 25, 2021 00:18 UTC
Pacelli Steven RobertManaging Dir., Dexcom Ventures
SaleCommon Stock 589 $360.36 $212,252.51
Disclosure

SEC source: 0001093557-21-000093 · edgardoc.xml · nonDerivative · entry 3

Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,874

F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F3 · price: This transaction was executed in multiple trades at prices ranging from $359.69 to $360.67. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

Read SEC document
March 23, 2021 Filed Mar 25, 2021 00:18 UTC
Pacelli Steven RobertManaging Dir., Dexcom Ventures
SaleCommon Stock 77 $358.13 $27,576.01
Disclosure

SEC source: 0001093557-21-000093 · edgardoc.xml · nonDerivative · entry 2

Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,463

F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

Read SEC document
March 23, 2021 Filed Mar 25, 2021 00:18 UTC
Pacelli Steven RobertManaging Dir., Dexcom Ventures
SaleCommon Stock 18 $352.88 $6,351.84
Disclosure

SEC source: 0001093557-21-000093 · edgardoc.xml · nonDerivative · entry 1

Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,540

F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

Read SEC document
March 23, 2021 Filed Mar 25, 2021 00:18 UTC
DOUBLEDAY RICHARDEVP Chief Commercial Officer
SaleCommon Stock 94 $362.45 $34,070.30
Disclosure

SEC source: 0001093557-21-000092 · edgardoc.xml · nonDerivative · entry 5

DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 6,654

F1 · shares: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee.

Read SEC document
March 23, 2021 Filed Mar 25, 2021 00:18 UTC
DOUBLEDAY RICHARDEVP Chief Commercial Officer
SaleCommon Stock 268 $361.37 $96,846.70
Disclosure

SEC source: 0001093557-21-000092 · edgardoc.xml · nonDerivative · entry 4

DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 6,748

F1 · shares: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F4 · price: This transaction was executed in multiple trades at prices ranging from $360.94 to $361.83. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee.

Read SEC document
March 23, 2021 Filed Mar 25, 2021 00:18 UTC
DOUBLEDAY RICHARDEVP Chief Commercial Officer
SaleCommon Stock 655 $360.33 $236,017.66
Disclosure

SEC source: 0001093557-21-000092 · edgardoc.xml · nonDerivative · entry 3

DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 7,016

F1 · shares: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F3 · price: This transaction was executed in multiple trades at prices ranging from $359.70 to $360.67. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee.

Read SEC document
March 23, 2021 Filed Mar 25, 2021 00:18 UTC
DOUBLEDAY RICHARDEVP Chief Commercial Officer
SaleCommon Stock 74 $358.13 $26,501.62
Disclosure

SEC source: 0001093557-21-000092 · edgardoc.xml · nonDerivative · entry 2

DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 7,671

F1 · shares: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee.

Read SEC document
March 23, 2021 Filed Mar 25, 2021 00:18 UTC
DOUBLEDAY RICHARDEVP Chief Commercial Officer
SaleCommon Stock 18 $352.88 $6,351.84
Disclosure

SEC source: 0001093557-21-000092 · edgardoc.xml · nonDerivative · entry 1

DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 7,745

F1 · shares: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee.

Read SEC document
March 18, 2021 Filed May 25, 2021 23:15 UTC OtherCommon Stock 2,192 $0.00 $0.00
Disclosure

SEC source: 0001093557-21-000135 · edgardoc.xml · nonDerivative · entry 3

AUGUSTINOS NICHOLAS · CIK 0001238485 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 7,900

F1 · shares: Shares were transferred from ownership under the Kirschner/Augustinos Revocable Trust to direct ownership.

F5 · balance_after: Shares are held by the Kirschner/Augustinos Revocable Trust, of which the reporting person is trustee.

Read SEC document
March 18, 2021 Filed May 25, 2021 23:15 UTC OtherCommon Stock 2,192 $0.00 $0.00
Disclosure

SEC source: 0001093557-21-000135 · edgardoc.xml · nonDerivative · entry 1

AUGUSTINOS NICHOLAS · CIK 0001238485 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,998

F1 · shares: Shares were transferred from ownership under the Kirschner/Augustinos Revocable Trust to direct ownership.

F2 · balance_after: Included in this number are 806 restricted stock units which were granted on May 22, 2020 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2021 Annual Meeting.

Read SEC document
March 11, 2021 Filed Mar 12, 2021 22:41 UTC
Selvaraj Shelly RamasamySVP Information Technology
SaleCommon Stock 1,867 $355.86 $664,390.62
Disclosure

SEC source: 0001093557-21-000078 · edgardoc.xml · nonDerivative · entry 2

Selvaraj Shelly Ramasamy · CIK 0001805707 · SVP Information Technology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,136

F3 · shares: On May 30, 2019, Mr. Selvaraj adopted a 10b5-1 Plan which was amended on May 11, 2020. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Selvaraj. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · balance_after: Included in this number are 9,484 unvested restricted stock units, 3,073 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,655 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 2,756 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

Read SEC document
March 10, 2021 Filed Mar 12, 2021 22:42 UTC
Sylvain Jereme MSVP, Finance & CAO
SaleCommon Stock 941 $362.92 $341,504.90
Disclosure

SEC source: 0001093557-21-000079 · edgardoc.xml · nonDerivative · entry 1

Sylvain Jereme M · CIK 0001681267 · SVP, Finance & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,108

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: Included in this number are 11,837 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,654 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 1,608 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 1,274 of which were granted on November 8, 2018 and shall vest through November 8, 2021.

Read SEC document
March 10, 2021 Filed Mar 12, 2021 22:41 UTC
Selvaraj Shelly RamasamySVP Information Technology
SaleCommon Stock 2,700 $362.92 $979,875.90
Disclosure

SEC source: 0001093557-21-000078 · edgardoc.xml · nonDerivative · entry 1

Selvaraj Shelly Ramasamy · CIK 0001805707 · SVP Information Technology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,003

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: Included in this number are 9,484 unvested restricted stock units, 3,073 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,655 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 2,756 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

Read SEC document
March 10, 2021 Filed Mar 12, 2021 22:40 UTC
SAYER KEVIN RDirector · Chairman, CEO & President
SaleCommon Stock 14,044 $362.92 $5,096,806.35
Disclosure

SEC source: 0001093557-21-000077 · edgardoc.xml · nonDerivative · entry 1

SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 117,478

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: Included in this number are 42,356 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 11,943 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

Read SEC document
March 10, 2021 Filed Mar 12, 2021 22:40 UTC
Pacelli Steven RobertEVP Strategy and Corporate Dev
SaleCommon Stock 5,566 $362.92 $2,019,996.02
Disclosure

SEC source: 0001093557-21-000076 · edgardoc.xml · nonDerivative · entry 1

Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,558

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

Read SEC document
March 10, 2021 Filed Mar 12, 2021 22:39 UTC
Murphy Patrick MichaelEVP, Chief Legal Officer
SaleCommon Stock 3,471 $362.92 $1,259,684.91
Disclosure

SEC source: 0001093557-21-000075 · edgardoc.xml · nonDerivative · entry 1

Murphy Patrick Michael · CIK 0001692785 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,241

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: Included in this number are 15,413 unvested restricted stock units, 5,634 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,905 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

Read SEC document
March 10, 2021 Filed Mar 12, 2021 22:38 UTC
Leach Jacob StevenEVP Chief Technology Officer
SaleCommon Stock 5,353 $362.92 $1,942,694.70
Disclosure

SEC source: 0001093557-21-000074 · edgardoc.xml · nonDerivative · entry 1

Leach Jacob Steven · CIK 0001700255 · EVP Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,396

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: Included in this number are 19,999 unvested restricted stock units, 7,171 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 7,832 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

Read SEC document
March 10, 2021 Filed Mar 12, 2021 22:38 UTC
Blackford Quentin S.Chief Operating Officer & CFO
SaleCommon Stock 6,509 $362.22 $2,357,688.03
Disclosure

SEC source: 0001093557-21-000073 · edgardoc.xml · nonDerivative · entry 1

Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,165

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: Included in this number are 37,709 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 6,144 of which were granted on March 8, 2019 and shall vest through March 8, 2022 and 15,590 of which were granted on September 7, 2017 and shall vest through September 7, 2021.

Read SEC document
March 10, 2021 Filed Mar 12, 2021 22:37 UTC SaleCommon Stock 5,566 $362.92 $2,019,996.02
Disclosure

SEC source: 0001093557-21-000072 · edgardoc.xml · nonDerivative · entry 1

Balo Andrew K · CIK 0001323190 · *

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,307

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

Read SEC document
March 10, 2021 Filed Mar 12, 2021 22:36 UTC
Abbey DonaldEVP Quality and Regulatory Aff
SaleCommon Stock 5,566 $362.92 $2,019,996.02
Disclosure

SEC source: 0001093557-21-000071 · edgardoc.xml · nonDerivative · entry 1

Abbey Donald · CIK 0001534342 · EVP Quality and Regulatory Aff

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,937

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: Included in this number are 16,171 restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

Read SEC document
March 09, 2021 Filed Mar 11, 2021 00:29 UTC
Selvaraj Shelly RamasamySVP Information Technology
SaleCommon Stock 152 $356.94 $54,254.88
Disclosure

SEC source: 0001093557-21-000056 · edgardoc.xml · nonDerivative · entry 2

Selvaraj Shelly Ramasamy · CIK 0001805707 · SVP Information Technology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,703

F3 · shares: On May 30, 2019, Mr. Selvaraj adopted a 10b5-1 Plan which was amended on May 11, 2020. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Selvaraj. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · balance_after: Included in this number are 9,484 unvested restricted stock units, 3,073 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,655 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 2,756 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

Read SEC document
March 09, 2021 Filed Mar 11, 2021 00:29 UTC
SAYER KEVIN RDirector · Chairman, CEO & President
SaleCommon Stock 200 $364.33 $72,866.00
Disclosure

SEC source: 0001093557-21-000055 · edgardoc.xml · nonDerivative · entry 9

SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 131,522

F5 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2020, and amended effective December 16, 2020. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer.

F11 · price: This transaction was executed in multiple trades at prices ranging from $364.00 to $364.99. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F4 · balance_after: Included in this number are 42,356 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 11,943 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

Read SEC document
March 09, 2021 Filed Mar 11, 2021 00:29 UTC
SAYER KEVIN RDirector · Chairman, CEO & President
SaleCommon Stock 574 $362.87 $208,289.73
Disclosure

SEC source: 0001093557-21-000055 · edgardoc.xml · nonDerivative · entry 8

SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 131,722

F5 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2020, and amended effective December 16, 2020. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer.

F10 · price: This transaction was executed in multiple trades at prices ranging from $362.58 to $363.51. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F4 · balance_after: Included in this number are 42,356 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 11,943 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

Read SEC document
March 09, 2021 Filed Mar 11, 2021 00:29 UTC
SAYER KEVIN RDirector · Chairman, CEO & President
SaleCommon Stock 1,127 $362.29 $408,304.21
Disclosure

SEC source: 0001093557-21-000055 · edgardoc.xml · nonDerivative · entry 7

SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 132,296

F5 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2020, and amended effective December 16, 2020. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer.

F9 · price: This transaction was executed in multiple trades at prices ranging from $361.58 to $362.55. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F4 · balance_after: Included in this number are 42,356 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 11,943 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

Read SEC document
March 09, 2021 Filed Mar 11, 2021 00:29 UTC
SAYER KEVIN RDirector · Chairman, CEO & President
SaleCommon Stock 700 $361.02 $252,711.41
Disclosure

SEC source: 0001093557-21-000055 · edgardoc.xml · nonDerivative · entry 6

SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 133,423

F5 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2020, and amended effective December 16, 2020. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer.

F8 · price: This transaction was executed in multiple trades at prices ranging from $360.44 to $361.43. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F4 · balance_after: Included in this number are 42,356 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 11,943 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

Read SEC document
March 09, 2021 Filed Mar 11, 2021 00:29 UTC
SAYER KEVIN RDirector · Chairman, CEO & President
SaleCommon Stock 550 $359.82 $197,902.49
Disclosure

SEC source: 0001093557-21-000055 · edgardoc.xml · nonDerivative · entry 5

SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 134,123

F5 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2020, and amended effective December 16, 2020. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer.

F7 · price: This transaction was executed in multiple trades at prices ranging from $359.44 to $360.22. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F4 · balance_after: Included in this number are 42,356 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 11,943 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

Read SEC document
March 09, 2021 Filed Mar 11, 2021 00:29 UTC
SAYER KEVIN RDirector · Chairman, CEO & President
SaleCommon Stock 400 $358.75 $143,498.52
Disclosure

SEC source: 0001093557-21-000055 · edgardoc.xml · nonDerivative · entry 4

SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 134,673

F5 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2020, and amended effective December 16, 2020. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer.

F6 · price: This transaction was executed in multiple trades at prices ranging from $358.40 to $359.35. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F4 · balance_after: Included in this number are 42,356 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 11,943 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

Read SEC document
March 09, 2021 Filed Mar 11, 2021 00:29 UTC
SAYER KEVIN RDirector · Chairman, CEO & President
SaleCommon Stock 306 $356.94 $109,223.64
Disclosure

SEC source: 0001093557-21-000055 · edgardoc.xml · nonDerivative · entry 3

SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 135,073

F5 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2020, and amended effective December 16, 2020. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer.

F4 · balance_after: Included in this number are 42,356 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 11,943 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

Read SEC document
March 08, 2021 Filed Mar 11, 2021 00:30 UTC
Sylvain Jereme MSVP, Finance & CAO
GrantCommon Stock 5,301 $0.00 $5.30
Disclosure

SEC source: 0001093557-21-000058 · edgardoc.xml · nonDerivative · entry 1

Sylvain Jereme M · CIK 0001681267 · SVP, Finance & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,049

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

F2 · balance_after: Included in this number are 11,837 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,654 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 1,608 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 1,274 of which were granted on November 8, 2018 and shall vest through November 8, 2021.

Read SEC document
March 08, 2021 Filed Mar 11, 2021 01:23 UTC
Leach Jacob StevenEVP Chief Technology Officer
GrantCommon Stock 7,171 $0.00 $7.17
Disclosure

SEC source: 0001093557-21-000061 · edgardoc.xml · nonDerivative · entry 1

Leach Jacob Steven · CIK 0001700255 · EVP Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,749

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

F2 · balance_after: Included in this number are 19,999 unvested restricted stock units, 7,171 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 7,832 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

Read SEC document
March 08, 2021 Filed Mar 11, 2021 00:29 UTC
Stern SadieEVP Chief Human Resources Off
GrantCommon Stock 5,634 $0.00 $5.63
Disclosure

SEC source: 0001093557-21-000057 · edgardoc.xml · nonDerivative · entry 1

Stern Sadie · CIK 0001797971 · EVP Chief Human Resources Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,841

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

F2 · balance_after: Included in this number are 13,841 unvested restricted stock units, 5,634 of which were granted on March 8, 2021 and shall vest through March 8, 2024, and 8,207 of which were granted on November 19, 2020 and shall vest through November 19, 2024.

Read SEC document
March 08, 2021 Filed Mar 11, 2021 00:29 UTC
Selvaraj Shelly RamasamySVP Information Technology
GrantCommon Stock 3,073 $0.00 $3.07
Disclosure

SEC source: 0001093557-21-000056 · edgardoc.xml · nonDerivative · entry 1

Selvaraj Shelly Ramasamy · CIK 0001805707 · SVP Information Technology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,855

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

F2 · balance_after: Included in this number are 9,484 unvested restricted stock units, 3,073 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,655 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 2,756 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

Read SEC document
March 08, 2021 Filed Mar 11, 2021 00:29 UTC
SAYER KEVIN RDirector · Chairman, CEO & President
GrantCommon Stock 13,445 $0.00 $13.45
Disclosure

SEC source: 0001093557-21-000055 · edgardoc.xml · nonDerivative · entry 2

SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 135,379

F3 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

F4 · balance_after: Included in this number are 42,356 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 11,943 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.